News
-
-
PRESS RELEASE
Neovii Advances FDA Fast Track-Designated ATLG Program in Type 1 Diabetes with Pivotal Phase 2 study // Company appoints physician-scientist Salvatore Alesci as Chief Medical Officer
Neovii Pharmaceuticals AG advances ATLG Program in Type 1 Diabetes with pivotal Phase 2 study and appoints Salvatore Alesci as Chief Medical Officer -
-
-
-
-
-
-
-